Investor Presentation
December 2023
Copyright 2023. All rights reserved.
Forward Looking Statements
This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and expectations of management with respect to the Company's industry, growth and strategy, including the Company's focus on securing more multi-unit orders with large network operators and its ability to obtain sustainable, long-term growth, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the expected benefits of the acquisition of HMC, (v) number or percentage
of patients or workers that could potentially benefit from the Company's products, (vi) potential technological and operational improvements and timing, including with products such as Nomad and (vii) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv), (v) or (vi) above. Forward-looking statements can be identified by words such as "expect," "continue," "anticipate," "estimate," "believe," "plan," "projection," "grow," "potential," "future," "can," "develop," "proposition," "position," "expand" or words of similar meaning.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or
enhance the Company's technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad
market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, the Company's ability to successfully integrate the HMC business and its personnel and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and
described in more detail in the Company's public filings with the Securities and Exchange Commission ("SEC"). You should carefully read the Cautionary Note Regarding Forward-Looking
Statements and the factors described in the "Risk Factors" section of the Company's public filings with the SEC to better understand the risks and uncertainties inherent in the Company. The Company does not undertake to update these forward-looking statements, except as required by law.
This presentation includes a discussion of cash flow, which is a financial measure that is not calculated in accordance with GAAP. For more information regarding cash flow, please see slide 20.
© 2023 Ekso Bionics, Inc | 2 |
Our Mission
To amplify human motion by enhancing strength, endurance and mobility across medical and industrial applications with advanced robotics.
Copyright 2022. All rights reserved.
Copyright 2023. All rights reserved.
History
2002 UC Berkeley DARPA Project to assist US soldiers
2009 HULC prototype, licensed to Lockheed Martin
2000s
2018
Launch of EksoVest for manufacturing
2014 Ekso Bionics becomes publicly traded company
2010s
2020
Launch of EVO
EksoNRreceives | 2022 |
FDA clearance for | |
EksoNRreceives | |
ABI | |
FDA clearance for | |
MS |
2020s
2005
Company founded
Berkeley Bionics
2006 Won $2M grant for development of medical exoskeleton
2016
Ekso GT receives FDA clearance for SCI & stroke
Ekso Bionics listed on
NASDAQ
2012
Launched Ekso GT, first commercial medical rehabilitation exoskeleton
2019 | 2022 |
Launch of | |
Ekso Bionics | |
EksoNR | |
acquires Indego | |
from Parker Hannifin
© 2023 Ekso Bionics, Inc
4
Business Segments in Wearable Exoskeletons
Enterprise | Personal | Industrial |
Neuro-rehabilitation treatment via acute care, inpatient rehabilitation | Home and community use by individuals utilizing personal exoskeletons | Overhead support in automotive, aerospace, commercial |
construction, renewable energy, logistics, general | ||
hospitals (IRFs), outpatient rehab facilities, & VA medical centers | ||
manufacturing, residential construction, and more | ||
THERAPY | PERSONAL |
© 2023 Ekso Bionics, Inc | 5 |
Enterprise
Elevating the standard of care for Neurorehabilitation for stroke, brain injury (ABI), MS, and SCI
CLICK TO WATCH VIDEO
- Improved post-stroke affected side and engagement of environment¹
- Eliminates compensations while walking in the device, elevates precision in movement2
- High repetition, increased dosage, and intensity³
- Facilitates task-oriented exercises⁴
- Reduces therapist workload and risk of injury to patient/therapist⁵
- Promotes neuroplasticity and improved outcomes¹
- Calabrò R.S., Antonino Naro, Margherita Russo, Placido Bramanti, Luigi Carioti, Tina Balletta, Antonio Buda, Alfredo Manuli, Serena Filoni and Alessia Bramanti. Shaping neuroplasticity by using powered exoskeletons in patients with stroke: a randomized clinical trial. Journal of NeuroEngineering and Rehabilitation (2018).
- Swank C, Almutairi S, Wang-Price S, Gao F; Published in Topics in Stroke Rehabilitation. 2020 Oct;27(7):503-515. doi: 10.1080/10749357.2020.1728954
- Nolan K, Karunakaran KK, Chervin K,MonfettMR, BapineeduRK, JaseyNN, Oh-Park M. Robotic exoskeleton gait training during acute stroke inpatient rehabilitation. Frontiers in Neurorobotics October 2020 (14).
- Nolan KJ, et al. Utilization of Robotic Exoskeleton for Overground Walking in Acute and Chronic Stroke. FrontNeurorobot. 2021 Sep 1;15:689363.
- Murray SA, Ha KH, Goldfarb M. An Assistive Controller for a Lower-Limb Exoskeleton for Rehabilitation after Stroke, and Preliminary Assessment Thereof. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:4083-6.doi: 10.1109/EMBC.2014.6944521.
© 2023 Ekso Bionics, Inc | 6 |
Economic Value Proposition for Neuro-rehab Providers
Economic Drivers
EksoNR & Ekso Indego Therapy can increase revenue by:
- Increase Revenue / Patient
Patients can undergo longer treatment at higher reimbursement
- Attract New Patient Volume
ART attracts incremental patients
- Increase Patient Throughput
Patients can improve faster, increasing a center's throughput
IV. Flexible Acquisition Options
Capital Purchase / Capital Lease
Subscription / Operational Lease
- Ekso Bionics EksoNR Customer, Internal Study
- Ekso Bionics EksoNR Customer, Internal Study (OhioHealth)
Customer Case Studies
I. Increase Revenue / Patient 1
- Attract New Patients 2
- 8% increase in # of stroke patients (45incremental)
- Each patient represents $18,000 of revenue
- EksoNR attracted over $850,000 of new revenue
- Increase Patient Throughput2
- Average length of stay decreased from 15.9 days to 14.1 days
- ~13% improvement in effective patient throughput
© 2023 Ekso Bionics, Inc | 7 |
Personal
Enabling independence in the SCI community
CLICK TO
WATCH VIDEO
CLICK TO
WATCH VIDEO
"Mentally feeling good from within because I got to exercise, walk and
talk with people in a standing position, not seated, brings me great joy. Gives me hope for the future, Ekso Indego fulfills both my physical and mental state."
- Melanie, Indego User
© 2023 Ekso Bionics, Inc
Synergies with Enterprise:
- Individuals with SCI often rehab with Ekso products in Post Acute Care
Indego's Competitive Advantage
- Fastest exoskeleton walking speeds
- Ease of use
- Lightest exoskeleton, modular
- Transports, dons, and stores easily
- Wireless operation with Indego app
User reported benefits:
- Improved quality of life and mental health¹
- Improved functional mobility and trunk control¹
-
Improved spasticity, neuropathic pain, bowel and bladder function¹
1. Ekso Bionics Indego Customers, survey
8
Global Presence
Largest mobile exoskeleton footprint globally with
450+ centers, 800+ devices deployed, 100s of millions of steps
Ekso West
(Global HQ)
San Rafael, CA
Direct
Distributor
EMEA Headquarters
Hamburg, GE
Ekso East
Macedonia, OH
APAC Headquarters
Singapore
© 2023 Ekso Bionics, Inc | 9 |
Continuum of Care & Market Opportunity
Ekso can follow our patients through their rehabilitative process from hospital to home
Enterprise Health | Personal Health | |
Expanding Reach: | Growth Opportunities: |
Post-Acute Care
Acute Care
Indego acquisition expands | Home / community use for SCI |
to better reach Outpatient | patients through VA and CMS |
Facilities |
Inpatient Rehab
Facility (IRF)
~1,200 centers1
~16% penetration
Outpatient | Wellness Centers | Home/Community | ||
Long Term Acute | Skilled Nursing | ~63,000 centers | Emerging Market | • Veterans |
• Home health | ||||
Care (LTACH) | Facility (SNF) | Expanded Market | ~31,000 centers in | |
• ~100 personal devices | ||||
~340 centers1 | ~18,700 centers2 | |||
Opportunity: ~$875m - $1.3B | the US | delivered | ||
Expected expanded market opportunity +$300m in VA3 | |
Annual Global Market Opportunity: ~$650m - $900m | Anticipated significant growth through CMS4 |
1. https://cms.gov | |
2. http://www.definitivehc.com | |
3. Ekso Bionics, estimate. Informed by interviews with VA physicians and medical staff at VA SCI/D facilities | |
4. Ekso Bionics, slide 12. CMS codification and reimbursement for powered exoskeletons as a brace |
© 2023 Ekso Bionics, Inc | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ekso Bionics Holdings Inc. published this content on 18 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 December 2023 13:08:02 UTC.